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Ecto-ATPase (CD39L1) corresponds to the type 2 en-
zyme of the ecto-nucleoside triphosphate diphosphohy-
drolase family (E-NTPDase). We have isolated from hu-
man ECV304 cells three cDNAs with high homology with
members of the E-NTPDase family that encode pre-
dicted proteins of 495, 472, and 450 amino acids. Se-
quencing of a genomic DNA clone confirmed that these
three sequences correspond to splice variants of the
human ecto-ATPase (NTPDase2, -2, and -2). Although
all three enzyme forms were expressed heterologously
to similar levels in Chinese hamster ovary cells clone
K-1 (CHO-K1) cells, only the 495-amino acid protein
(NTPDase2 exhibited ecto-ATPase activity. Immunolo-
calization studies demonstrated that NTPDase2 is fully
processed and trafficked to the plasma membrane,
whereas the NTPDase2 and -2 splice variants were
retained in not fully glycosylated forms in the endoplas-
mic reticulum. The potential roles of two highly con-
served residues, Cys399 and Asn443, in the activity and
cellular trafficking of the ecto-ATPase were examined.
Mutation of Cys399, which is absent in NTPDase2 and
-2, produced a protein completely devoid of nucleotid-
ase activity, while mutation of Asn443 to Asp resulted in
substantial loss of activity. Neither the Cys399 nor Asn443
mutants were fully glycosylated, and both were retained
in the endoplasmic reticulum. These results indicate
that the lack of ecto-nucleotidase activity exhibited by
NTPDase2 and -2 and the C399S mutant, as well as the
large reduction of activity in the N443D mutant are due
to alterations in the folding/maturation of these
proteins.
Extracellular nucleotides modulate many physiological re-
sponses through interaction with G protein-coupled metabo-
tropic receptors (P2Y) and ligand-gated ionotropic receptors
(P2X) (1–3). Termination of nucleotide-promoted signaling is
accomplished by rapid degradation and/or interconversion of
extracellular nucleotides by ecto-nucleotidases. Although the
primary function of ecto-nucleotidases involves the hydrolysis
of extracellular nucleotides, the complete physiological signifi-
cance of these enzymes is not fully understood. For example,
ecto-nucleotidases also have been implicated in physiological
phenomena as diverse as cell adhesion (4), purine recycling (5),
pain transmission (6), immune function (7), blood hemostasis
(8), and others (9, 10).
The ecto-nucleoside triphosphate diphosphohydrolases
(E-NTPDases)1 are a family of ecto-nucleotidases, including
ecto-ATPases and ecto-ATPDases (apyrases), that hydrolyze
nucleoside 5-tri- and diphosphates with isozyme-dependent
nucleotide selectivities and biochemical properties. The
E-NTPDase family includes membrane-associated enzymes
(NTPDase1 to NTPDase4) and soluble enzymes (NTPDase5
and NTPDase6) (see Zimmermann (10) for a review).
NTPDase2 (also known as ecto-ATPase or CD39L1) exhibits a
strong preference for nucleoside triphosphates (NTPs) over
diphosphates (nucleoside diphosphates), hydrolyzing nuc-
leoside diphosphates at 3–5% of the rate of NTPs (10–14).
NTPDase2 contains two transmembrane domains with very
short cytoplasmic amino and carboxyl termini and a large
extracellular loop comprising the catalytic site. Five apyrase
conserved regions (ACRs) are common to all members of the
E-NTPDase family and presumably are important for enzy-
matic activity (15–17). NTPDase2 requires millimolar concen-
trations of divalent cations (Ca2 or Mg2) and hydrolyzes all
naturally occurring nucleoside 5-triphosphates. Genes encod-
ing NTPDase2 have been cloned from chicken gizzard (13), rat
brain (11), mouse hepatoma cells (18), and a human bladder
epithelial cell line (14). Sequence analysis of the predicted
protein suggests that the human NTPDase2 contains six po-
tential N-glycosylation sites and 10 highly conserved cysteine
residues that may be involved in formation of disulfide bonds
important for structure and enzymatic activity (17, 19, 20).
A human ecto-ATPase sequence named CD39L1 was re-
ported previously (21). Although enzyme activity was not meas-
ured, this sequence exhibited a high degree of homology with
NTPDase2 (57–83%) and NTPDase1 (40–50%) from different
species. Sequence comparisons of this protein from different
species indicated that CD39L1 lacked a 23-amino acid se-
quence in the putative extracellular loop between ACR4 and
ACR5. The full-length human ecto-ATPase was cloned and its
activity determined (14). Thus, the possibility of the existence
of splice variants for the human ecto-ATPase was established
(14). A novel rat ecto-ATPase mRNA was identified that con-
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tains an additional 193-bp exon arising from alternative splic-
ing in the 3-end of the gene (22). Splice variants also were
reported for the related ecto-nucleotide pyrophosphatase/phos-
phodiesterase family (E-NPP), where human phosphodiester-
ase-I (PD-I) and autotaxin likely represent splice variants of
the NPP2 gene (23–26)
In this study we delineate the genomic organization of the
human ecto-ATPase gene and describe three splice variants of
the human NTPDase2 gene encoding proteins of 495, 472, and
450 amino acids, respectively. Additionally, we demonstrate
the importance of Cys399 for correct processing and trafficking
to plasma membrane of the human NTPDase2. Absence of this
residue is likely responsible for the lack of activity exhibited by
the shorter splice variants of the enzyme, probably due to an
impaired disulfide bond necessary for maintaining structure of
the enzyme.
EXPERIMENTAL PROCEDURES
Materials—ATP was from Research Biochemicals Inc. (Natick, MA).
All other nucleotides and adenosine were from Roche Applied Science
(Mannheim, Germany). Anti-Myc monoclonal antibody (9E10) and
pcDNA4/Myc-His(B) mammalian expression vector were from Invitro-
gen (Carlsbad, CA). Anti penta-His monoclonal antibody was obtained
from Qiagen (Valencia, CA). RedivueTM [32P]dCTP (10 mCi/ml) was
from Amersham Biosciences. Digitonin was from Calbiochem. Triton
X-100, Nonidet P-40, and CHAPS were obtained from Pierce. N-Dode-
cyl--D-maltoside was from Dojindo Labs (Gaithersburg, MD). Lipo-
fectAMINE2000 reagent was purchased from Invitrogen. KH2PO4
standard solution was from Sigma. Flavobacterium meningosepticium
peptide:N-glycosidase F (PNGase F) was obtained from New England
Biolabs, Inc. (Beverly, MA). Polyclonal antibodies against the trans-
Golgi network (TGN38) were kindly provided by Dr. Sharon Milgram
(Department of Cellular and Molecular Physiology at University of
North Carolina-Chapel Hill). All tissue culture reagents were from the
Lineberger Comprehensive Cancer Center tissue culture facility at the
University of North Carolina. Sources of other products were reported
previously (27).
Cell Culture—ECV304 human bladder tumor epithelial cells were
grown in 199 medium supplemented with 10% fetal calf serum, 50
units/ml penicillin, and 50 g/ml streptomycin. Chinese hamster ovary
cells clone K-1 (CHO-K1) were grown in Ham’s F-12 nutrient mixture
supplemented with 10% fetal calf serum. NIH-3T3 mouse fibroblasts
were grown in DMEM supplemented with 10% bovine calf serum and
4.5 g/liter of glucose. All cells were maintained at 37 °C in a humidified
atmosphere of 5% CO2, 95% air.
Isolation of Splice Variants of the Human Ecto-ATPase—All DNA
and RNA manipulations were carried out according to standard proce-
dures (Sambrook et al. (44). The cDNAs encoding the splice variants of
the human ecto-ATPase were obtained by reverse transcriptase-PCR
amplification of mRNA from ECV304 cells. Messenger RNA was
isolated from ECV304 cultures using the Fast Track 2.0 kit (Invitro-
gen). First-strand cDNA synthesis was performed using 0.1 g of
mRNA as template and oligo(dT) as primer for the reverse transcriptase
(reverse transcriptase-PCR kit, Stratagene, La Jolla, CA). The PCR
reaction (100 l) was developed in the presence of 5.0 Units of Pfu DNA
polymerase (Stratagene) and contained 5 l of the cDNA obtained in
the reverse transcriptase reaction as the template and 0.4 M of each of
the amplification primers. The PCR primers were designed to amplify the
complete coding sequence of the human ecto-ATPase CD39L1 (Gen-
BankTM accession number U91510), and the amplified PCR products were
ligated into the retroviral expression vector pLXPIH as we described
previously (14). The PCR amplification products were absolutely depend-
ent on the presence of reverse transcriptase, indicating that the amplified
sequences originated from mRNA. The amplified sequences contained
open reading frames encoding predicted proteins of 495, 472, and 450
amino acids for the products obtained with the primers for CD39L1.
Site-directed Mutagenesis of Human Ecto-ATPase—Mutagenesis
of the full-length human ecto-ATPase (NTPDase2) was performed
by PCR. The oligonucleotides used for mutagenesis were as follows:
Cys399 3 Ser mutation: sense, 5-CGC CTG GCC GAC TAC TCC GCC
GGG GCC ATG TTC-3; antisense, 5-GAA CAT GGC CCC GGC GGA
GTA GTC GGC CAG GCG-3 and N443D mutation: sense, 5-CTC GGC
TAC ATG CTG GAC CTG ACC AAC CTG ATC-3; antisense, 5-GAT
CAG GTT GGT CAG GTC CAG CAT GTA GCC GAG-3 (the mutated
codons are underlined).
Cloning of Human Ecto-ATPase Isoforms and Mutant cDNAs into
pcDNA4/Myc-His Expression Vector—cDNAs encoding the three splice
variants of the human ecto-ATPase and the two mutants were sub-
cloned into the mammalian expression vector pcDNA4/Myc-His that
allows immunodetection of the recombinant proteins with antibodies
against Myc or hexa-His epitopes localized at the carboxyl terminus of
each of the fusion proteins. To subclone the cDNAs into
pcDNA4/Myc-His we took advantage of the EcoRI (5) and XbaI (3)
sites of the multicloning site. An XbaI site was generated by PCR in the
3-end of the coding sequence of the five cDNAs prior to the stop codon
and in frame with the Myc and His6 tags in pcDNA4/Myc-His. The
cDNAs cloned into the retoviral vector pLXPIH (14) were utilized as the
template for the PCR reactions. The sense primer internal to the coding
sequences was 5-TAC CTG GGA GCC ACA GCG GGT A-3, and the
antisense primer containing the new XbaI site at the 3-end of the
sequence was 5-GAG ATC TAG AAT GGT GCT TGG CAG CTT GGC
G-3 (the XbaI is underlined). The PCR amplification products of each
DNA were digested with BglII (unique restriction site present in the
five sequences) and XbaI and ligated with the smaller product of diges-
tion (EcoRI plus BglII) of pLXPIH-ecto-ATPase into pcDNA4/Myc-His
previously digested with EcoRI and XbaI. The resulting DNA con-
structs were amplified and purified (Qiagen). DNAs were sequenced at
the University of North Carolina-Chapel Hill Automated DNA Se-
quencing Facility on a model 377 DNA sequencer (PerkinElmer Life
Sciences, Applied Biosystems Division) using the ABI PRISM™ dye
terminator cycle sequencing ready reaction kit with AmpliTaq DNA
polymerase (PerkinElmer Life Sciences, Applied Biosystems Division).
DNA Genomic Library Screening and Sequencing—To isolate the
gene of the human ecto-ATPase we screened a Lambda FIX II genomic
library from human placenta (Stratagene). Total genomic DNA was
isolated from ECV304 cells (QIAamp blood kit, Qiagen) and used as
template for PCR amplification to generate a [32P]dCTP radiolabeled
oligonucleotide probe of 1,300 bp. Primers corresponding to the coding
region of CD39L1 were utilized: sense primer, 5-CAT CGT CCT GGA
TGC TGG TTC TTC ACA CAC GTC-3; antisense primer, 5-GGA CTG
GTT GTC TCA AAA GTG ATC TGG GTA GAG GCA CC-3. Positive
clones were purified from the plates, and phage DNA was amplified by
infecting TAP-90 cells. Following cell lysis, phage DNA was obtained
using the Lambda DNA Kit (Qiagen). Purified Lambda DNA was se-
quenced as described above.
Transient and Stable Transfection of CHO-K1 Cells—CHO-K1 cells
were plated at 75,000 cells/cm2. The cells were transfected by the
LipofectAMINE method 24 h later with empty vector or with
pcDNA4/Myc-His plasmid-DNA harboring the cDNAs corresponding to
the ecto-ATPase mutants or the three spliced forms of the enzyme.
Transfections were according to manufacturer’s indications using 0.4
g of DNA and 1.1 l of LipofectAMINE2000 per cm2 of tissue culture
area. Stable cell lines were isolated after growth of cells in the presence
of zeocin (200 g/ml).
Membrane Preparation—CHO-K1 cells stably expressing each DNA
construct were grown on 10-cm culture dishes. Confluent cell monolay-
ers were washed twice with ice-cold PBS, incubated for 20 min at 4 °C
in lysis buffer containing protease inhibitors (50 mM NaCl, 20 mM Tris,
pH 8.0, 2 g/ml aprotinin, 2 g/ml leupeptin, 1 mM phenylmethylsul-
fonyl fluoride, and 1 mM benzamidine), and harvested by scraping in the
same lysis buffer. The cells were collected, homogenized in a Potter
homogenizer, and centrifuged at 500  g for 10 min at 4 °C. The
supernatant was recovered for further centrifugation, and the pellet
was resuspended in lysis buffer, homogenized, and centrifuged. The
supernatants were combined and centrifuged at 45,000  g for 30 min
at 4 °C. The resulting pellet was resuspended in lysis buffer and cen-
trifuged under the same conditions. The final pellet was resuspended in
1 ml of lysis buffer supplemented with 250 mM sucrose and protease
inhibitors.
Assay of Ecto-ATPase Activity in Intact Cells and Membrane Prepa-
rations—Intact CHO-K1 cells stably or transiently expressing the two
mutants, the three isoforms of human ecto-ATPase, and vector control
were assayed in cells growing in 48-well plates 24 h after transfection
for transient expression or after cells reached confluence for stable cell
lines. Briefly, the cells were washed once with 1 ml of phosphate-free
saline solution (125 mM NaCl, 5.2 mM KCl, 20 mM HEPES, pH 7.4, 2 mM
CaCl2, 1.2 mM MgCl2, and 5 mM D-glucose), and incubated at 37 °C in
250 l final volume of the same medium containing the indicated
concentrations of nucleotide. The incubation was terminated by trans-
ferring the cell-free supernatants of each well to a new plate containing
50 l/well of 60 mM EDTA (10 mM final concentration) at 4 °C. The cell
supernatants were microwaved for 20 s to inactivate any released
nucleotidase activity and kept on ice until assayed for inorganic phos-
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phate content. Enzyme activity in total cell membrane preparations
was determined at 37 °C in 200 l of assay buffer (20 mM Tris, pH 7.4,
2 mM CaCl2, and 1.2 mM MgCl2) containing the indicated amount of
nucleotide as the substrate and 0.3–1.0 g of protein. Reactions were
stopped by the addition of 200 l of ice-cold 20 mM EDTA. Nucleotide
hydrolysis was assayed by the release of inorganic phosphate.
Phosphate Assay—Inorganic phosphate was determined colorimetri-
cally using a modification of the malachite green-based assay (28).
Supernatants (30 l) from cell lysates or 100 l of the membrane
fraction were combined with 100 l of malachite green reagent and the
absorbance determined at 595 nm in a plate reader (PerkinElmer Life
Sciences, model HTS 7000 bioassay reader). The inorganic phosphate
content was determined by comparison against a standard curve con-
structed with known amounts of phosphate.
Western Blot Analysis—SDS-polyacrylamide gel electrophoreis was
performed according to standard procedures (29). Membrane proteins,
usually 5–10 g per lane, were dissolved in reducing Laemmli’s sample
buffer (2% SDS, 10% glycerol, 0.02% bromphenol blue, 65 mM Tris, pH
6.8, and 5% 2-mercaptoethanol), separated on 5–8% polyacrylamide
gels, and electrophoretically transferred to a nitrocellulose membrane
(Bio-Rad). The membrane was probed with mouse monoclonal antibody
against Myc or hexa-His epitopes in 5% milk in TBS (20 mM Tris, pH
7.2, 120 mM NaCl, 0.1% Tween 20). Bands were visualized by chemilu-
minescence after incubation with horseradish peroxidase-conjugated
goat anti-mouse IgG as the secondary antibody (Pierce).
Immunocytochemistry Analysis—The recombinant proteins were lo-
calized by indirect immunofluorescence using the following protocol.
CHO-K1 cells stably expressing the Myc- and His6-tagged mutants and
splice variants of the human ecto-ATPase were grown in glass cover-
slips for 24 h, washed with PBS, and fixed for 5–10 min in 4% paraform-
aldehyde at room temperature. The cells were washed with PBS and
permeabilized for 4 min in 100% ethanol at 20 °C and subsequently
blocked in blocking solution (12.5% (w/v) normal goat serum in PBS) for
1–2 h at room temperature. Anti-Myc antibody (dilution, 1:500) alone or
in combination with TGN38 (dilution 1:800), a polyclonal antibody
against vesicles of the trans-Golgi network (30), were added in blocking
solution and incubated for 1–2 h at room temperature. After washing
with PBS, the cells were incubated for 1 h with fluorescently labeled
secondary antibodies: anti-mouse conjugated to Texas Red (dilution
1:200) or anti-rabbit conjugated to fluorescein isothiocyanate (dilution
1:200). In some experiments the cells were co-stained with fluorescein-
labeled phalloidin (dilution 1:50) or alexa-concanavalin A (1:300). Both
reagents were added together with the secondary antibody. After wash-
ing with PBS, the coverslips were mounted in Vectashield medium
containing 4,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories
Inc., Burlingame, CA). Photomicrographs were taken using a Leica TCS
4D confocal microscope and analyzed using Metamorph software (Uni-
versal Image Co.).
Protein Assay—Protein concentrations were determined according to
the Bradford method (31) using the Bio-Rad protein assay dye reagent
(Bio-Rad). Bovine serum albumin was used as the standard.
RESULTS
Human Ecto-ATPase (NTPDase2) Splice Variants—Chad-
wick and Frischauf (21) reported the cloning and chromosomal
location of a human gene (named CD39L1) exhibiting high
homology to other ecto-ATPases (NTPDase2) and CD39 ecto-
apyrases (NTPDase types 1 and 3). Examination of the biolog-
ical activity of the protein expressed from this gene was not
reported. Using reverse transcriptase-PCR and primers corre-
sponding to the 5- and 3-untranslated regions of CD39L1, we
isolated three cDNAs from human ECV304 cells following the
procedure detailed under “Experimental Procedures.” The iso-
lated sequences contained open reading frames of 1485, 1416,
and 1350 bp, encoding predicted proteins of 495, 472, and 450
amino acids, respectively. The three sequences are identical
except that the cDNA encoding the 472-amino acid protein
apparently is an alternative splice variant missing the codons
for positions 384–406 found in the 495-amino acid protein and
the cDNA encoding the 450-amino acid protein is apparently an
alternative splice variant missing the codons for positions 384–
428 found in the 495-amino acid protein. The spliced sequences
are localized on the carboxyl-terminal region of the predicted
extracellular face of the proteins (Fig. 1A). All three sequences
contain the five ACRs that are present in other ecto-ATPases
and apyrases (15) and are presumed to be important for cata-
lytic activity of the enzyme (16, 17). Six conserved N-glycosy-
lation consensus sequences also are present in the three cDNAs
(14).
To confirm that the isolated sequences correspond to splice
variants of the enzyme, the genomic organization of the ecto-
ATPase gene was examined. A human genomic library was
screened, and a 9-kb clone encoding the entire coding se-
quence for the 495-amino acid ecto-ATPase was isolated. This
clone was sequenced, and a sequence spanning 6 kb contain-
ing nine exons interrupted by eight introns was delineated that
encoded the full-length 495-amino acid ecto-ATPase (Fig. 1B).
Sequence analysis revealed that the two cDNA sequences en-
coding the 472 and 450 amino acid proteins correspond to true
alternative spliced forms of the human ecto-ATPase gene. That
is, we identified the three alternative exon-intron flanking
sequences (Fig. 1B) that produced the full-length (human
NTPDase2) and the two alternative spliced forms,
NTPDase2 and -2. We previously reported that the 495-
amino acid form is a functional ecto-ATPase (14). Thus, the
cDNA of NTPDase2 (495 amino acids) contains the entire
eighth exon (135 bp), NTPDase2 (472 amino acids) contains
only the 66 bp at the 3-end of the eighth exon, and the eighth
exon is completely spliced out of NTPDase2 (450 amino acids)
(Fig. 1B). NTPDase2 corresponds to the DNA-sequence
named CD39L1 reported by Chadwick and Frischauf (21).
Splicing of the gene at the intron/exon boundaries indicated in
Fig. 1 does not change the open reading frame of any of the
three cDNAs reported here.
Expression of Myc- and Hexahistidine-tagged Splice Variants
of the Human NTPDase2—To study the expression and enzy-
matic activity of the splice variants of the human ecto-ATPase
(NTPDase2, -2, and -2), we constructed expression vectors
that incorporated Myc and hexa-His tags at the COOH termi-
nus of the proteins (see “Experimental Procedures”). Western
blot analyses indicated that all proteins were expressed at
similar levels after stable and transient expression in CHO-K1
cells (Fig. 2A). Anti-Myc and anti-polyhistidine antibodies de-
tected major bands of 66–70 kDa and a broad and very diffuse
band migrating at 75–80 kDa for the full-length recombinant
human ecto-ATPase (Fig. 2A). Essentially identical results
were obtained in a Western blot of the untagged full-length
ecto-ATPase blotted with anti-peptide polyclonal antibodies
against residues 387–401 (RVPGQRARLADYCAG) or against
the carboxyl terminus (LRQVHSAKLPSTI-COOH) of the hu-
man ecto-ATPase. Thus, the epitope tags had no effect on the
expression of the enzyme or on its mobility in SDS-PAGE (data
not shown). The electrophoretic mobilities of the shorter splice
variants of the ecto-ATPase (2 and 2) were reduced as pre-
dicted by their protein sequences (23 and 45 amino acids
shorter, respectively); interestingly, neither of these splice
variants exhibited the more diffuse upper species present in
the full-length enzyme (Figs. 2 and 3). Glycosylation appar-
ently accounts for the larger apparent size than that predicted
for the core non-glycosylated enzyme (54 kDa for the full-length
non-tagged and 57 kDa for the Myc-His-tagged protein). Con-
sistent with this conclusion, treatment of the three isoforms of
the human ecto-ATPase with F. meningosepticium PNGase F
resulted in single bands for the three proteins that migrated at
the expected size for the non-glycosylated amino acid backbones
(Fig. 2B). Taken together, these data suggest that the human
ecto-ATPase is initially synthesized as a core-glycosylated pre-
cursor that matures into a diffusely migrating fully glycosylated
polypeptide, which is known to be a common characteristic of
most secretory and plasma membrane glycoproteins (32).
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Ecto-nucleotidase Activity of the Spliced Forms of the Human
NTPDase2—We compared the enzymatic activity of the full-
length human ecto-ATPase (NTPDase2) with that of the 472
(NTPDase2) and 450 (NTPDase2) amino acid splice vari-
ants. Intact cells and membrane preparations from CHO-K1
cells were analyzed for hydrolytic activity 24 h after transient
expression of the proteins. CHO-K1 cells transfected with
empty vector exhibited negligible ecto-nucleotidase activity
during incubations up to 30 min in the presence of ATP (Fig. 3)
or ADP (data not shown) as substrates. In contrast, expression
of the full-length isozyme (NTPDase2) resulted in marked
ecto-nucleotidase activity against nucleoside triphosphates and
very little activity against nucleoside diphosphates, as ex-
pected for an NTPDase type 2 and as previously observed for
the non-tagged enzyme (10, 14). These results indicate that
tagging the protein in the COOH terminus does not affect its
enzymatic activity or substrate selectivity. Under the condi-
tions of this study, CHO-K1 cells transiently or stably express-
ing the full-length ecto-ATPase hydrolyzed more than half of
the substrate ATP in a 5-min incubation period (85.8  7.5
nmol of Pi/min/10
6 cells for ATP versus 4.7  0.5 nmol of
Pi/min/10
6 cells for ADP). Under the same conditions, measur-
able nucleotidase activity was not detected in cells expressing
NTPDase2 and NTPDase2, although these proteins were
expressed at the same level as the full-length protein (Fig. 3,
inset). Identical results were observed after expression of the
FIG. 1. Representation of the splicing events occurring in the human ecto-ATPase (NTPDase) gene and predicted protein
sequence of splice variants. A, diagram of the exon-intron map of the human ecto-ATPase gene. Boxes represent the nine exons (E1 through
E9), and the connecting lines represent the introns. The number of base pairs for each intron/exon are indicated. The splicing producing the three
protein coding sequences found in this study (E-NTPDase2, E-NTPDase2, and E-NTPDase2) is represented at the bottom of the diagram. The
zoomed diagram at the top illustrates the splicing events. Upper- and lowercase letters indicate exonic and intronic sequences as in E-NTPDase 2.
The consensus intron-exon boundaries are indicated in bold. B, predicted amino acid sequence of E-NTPDase 2. The 23 amino acids between
arrows 1 and 2 are missing in E-NTPDase2, and the 45 amino acids between arrows 1 and 3 are missing in E-NTPDase2.
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isozymes in NIH-3T3 mouse fibroblasts (data not shown).
Taken together, these results suggest that the region of the
human ecto-ATPase between residues 384 and 406 contains
important structural/functional determinants essential for en-
zymatic activity.
Identification of Important Cysteine and Asparagine Resi-
dues in the Human Ecto-ATPase—The sequence of the full-
length human ecto-ATPase was compared with other family
members to reveal possible explanations for the lack of activity
observed in the NTPDase2 and -2 splice variants. Both splice
variants retain the five ACRs known to be important for cata-
lytic activity. However, other possibilities for lack of activity in
the splice variants were considered. The human NTPDase2
contains 10 extracellular cysteine residues (amino acids 75, 99,
242, 265, 284, 310, 323, 328, 377, and 399) that are invariantly
conserved among the NTPDases type 1 (ecto-apyrases) and
type 2 (ecto-ATPases) from different species and that likely are
involved in formation of intra- or interchain disulfide bonds
important for the structure and function of these enzymes (17,
19, 20). One of these conserved cysteines, Cys399, is absent in
the 472 (NTPDase2) and 450 (NTPDase2) amino acid splice
variants of the human ecto-ATPase (Fig. 4). To assess the
functional significance of this highly conserved residue and to
determine whether its absence is responsible for the lack of
activity of the shorter splice forms of the human ecto-ATPase,
we mutated the cysteine at the 399 position to a serine, gener-
ating the mutant C399S.
Sequence analysis of the human ecto-ATPase also revealed
that only two (Asn64 and Asn443) out of the six potential N-
glycosylation sites (Asn64, Asn88, Asn129, Asn294, Asn378, and
Asn443) are conserved among all ecto-ATPases (NTPDase2)
from different species (human, mouse, rat, and chicken). N-
Linked glycosylation is a common co- and posttranslational
modification in many plasma membrane proteins (32), and it
likely is important for the function and oligomerization of E-
type ATPases and apyrases (7, 33–35). Since the glycosylation
pattern of the shorter splice variants clearly differs from the
full-length protein (Figs. 2 and 3), and since the proximity of an
aspartic acid (Asp65) to Asn64 makes this site improbable as a
glycosylation site (36), Asn443 was subjected to site-directed
mutagenesis to assess the role of N-glycosylation in ecto-
ATPase activity (Fig. 4). Thus, the asparagine at position 443
in the full-length human ecto-ATPase was replaced with an
aspartic acid, generating the mutant N443D.
Expression of the C399S and N443D Mutants of the Human
Ecto-ATPase in CHO-K1 Cells—The C399S and N443D mu-
tants of the human ecto-ATPase were produced and transiently
expressed in CHO-K1 cells. Equivalent levels of expression for
wild-type and mutant proteins were observed (Fig. 5A). The
C399S mutant exhibited an electrophoretic pattern similar to
that of the wild-type enzyme with the exception that the more
FIG. 2. Expression of Myc- and hexa-histidine-tagged splice
variants of the human ecto-ATPase in CHO-K1 cells. A, total
membrane preparations (10 g per lane) from CHO-K1 cells transiently
transfected with the cDNAs corresponding to the three splice variants
of the human ecto-ATPase and vector control were resolved by SDS-
PAGE, transferred to nitrocellulose, and the proteins detected with
anti-pentahistidine monoclonal antibodies. The arrow indicates the
fully matured species at 75–80 kDa in NTPDase2, which is absent in
2 and 2. B, the same membrane preparation used above (5 g per
lane) was treated in the absence () or in the presence () of 250 units
of PNGase F for 20 h at 37 °C, according to manufacturer’s instructions.
The proteins subsequently were separated by SDS-PAGE and analyzed
by immunoblotting with anti-Myc monoclonal antibodies. Prestained
molecular size markers are indicated in kilodaltons on the left.
FIG. 3. Enzymatic activity of splice variants of the human
ecto-ATPase. CHO-K1 cells (300,000 cells/well) were seeded into 12-
well plates, and the cells were transfected 24 h later with the cDNA
corresponding to the three splice variants of the human ecto-ATPase or
with empty vector. Twenty-four hours after transfection the ecto-
ATPase activity was determined as a function of time, at 37 °C, in 500
l of incubation medium in the presence of 500 M ATP (250 nmol). The
inset shows a Western blot of lysates from individual wells containing
the equivalent amount of cells tested for activity. The proteins were
detected with anti-pentahistidine monoclonal antibodies. Prestained
molecular size markers are indicated in kilodalton.
FIG. 4. Sequence comparison of conserved residues Cys399 and
Asn443 in the NTPDases1, -2, and -3. Sequences are aligned from 10
different ecto-enzymes. The cysteine and asparagine residues mutated
in the h-ATPase are boxed in the compared sequences. h, human; r, rat;
m, mouse; c, chicken; b, bovine.
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diffuse upper bands migrating at 75–80 kDa were not ob-
served. Interestingly, the N443D mutant migrated with the
same mobility as the smaller of the two major bands (doublet at
66–70 kDa) observed in the wild-type enzyme and the C399S
mutant (Fig. 5A). As observed for C399S, the diffuse bands at
75–80 kDa were absent in the N443D mutant (Figs. 5 and 6).
However, the apparent size of the N443D mutant was higher
than the predicted size of the amino acid backbone, suggesting
the presence of other glycosylated Asn residues. Consistent
with this observation, PNGase F treatment of membrane prep-
arations from cells expressing the wild-type enzyme or the
mutant proteins (Fig. 5B), or incubation of intact cells with
tunicamycin (data not shown), resulted in a unique band at the
expected size for the non-glycosylated core proteins (57 kDa).
These results indicate that Asn443 is a major N-glycosylation
target and that this site is normally glycosylated in the two
splice variants of the human ecto-ATPase.
Enzymatic Activity of the C399S and N443D Mutants of the
Human Ecto-ATPase—Mutation of Cys399 to serine resulted in
a protein completely devoid of ecto-ATPase activity (Fig. 6),
although no substantial differences were observed in protein
expression levels between the mutant and the fully active wild-
type enzyme (Fig. 6, inset). The N443D mutation resulted in an
enzyme with an ecto-ATPase activity that was 7% of that
observed with the wild-type enzyme (5.8  0.8 nmol of Pi/min/
106 cells versus 88.1  17.4 nmol of Pi/min/10
6 cells for the
wild-type enzyme with ATP as the substrate). Expression lev-
els of the N443D mutant were similar to those of the wild-type
enzyme (Fig. 6, inset).
Subcellular Localization of Splice Variants and C399S and
N443D Mutants of the Human Ecto-ATPase—Failure to target
to the plasma membrane could explain the lack/reduction of
activity of the splice variants (NTPDase2 and -2) and the
C399S and N443D mutants of the human ecto-ATPase. An
alternative explanation is that these proteins undergo struc-
tural modification or misfolding but are nonetheless normally
targeted to the cell surface. To address these possibilities, the
subcellular localization of the ecto-ATPases was determined
after stable expression in CHO-K1 cells. The wild-type
NTPDase2 exhibited a similar distribution as that of cortical
actin (which delimits the plasma membrane) detected by phal-
loidin staining (Fig. 7). The wild-type enzyme also exhibited a
dense perinuclear staining that co-localized with trans-Golgi
vesicles (Fig. 8), and a low level signal for the NTPDase2 also
overlapped with the endoplasmic reticulum (ER) marker con-
canavalin A (Fig. 8). Thus, most of the wild-type protein was
present either at the plasma membrane or in trans-Golgi ves-
icles likely in transit to the plasma membrane. In contrast,
neither of the shorter splice variants of the human ecto-
ATPase, NTPDase2 and -2, were localized at the plasma
membrane (Fig. 7). Both splice variants were entirely intracel-
lular, primarily in the ER (Fig. 7), since no co-localization of
NTPDase2 or -2 with trans-Golgi vesicles was observed (data
not shown). These results suggest that NTPDase2 and -2
displayed impaired trafficking to the plasma membrane, most
likely due to folding alterations that lead to retention in the
ER. The C339S and N443D mutants also accumulated intra-
cellularly (Fig. 8). Both mutant proteins exhibited no expres-
sion at the plasma membrane (Fig. 8), or in the trans-Golgi
network (data not shown), and were found mostly in the ER
(Fig. 8).
Enzyme Solubilization—The subcellular localization analy-
ses suggested that the lack/reduction in activity of the shorter
splice variants and mutants of the human ecto-ATPase may be
due to failure of these proteins to reach the plasma membrane.
For example, the most common mutation (F508) of the cystic
fibrosis transmembrane conductance Cl channel regulator,
results in a protein that retains activity although trapped in
FIG. 5. Expression of Myc- and hexahistidine-tagged wild-type
enzyme and the C399S and N443D mutants of the human ecto-
ATPase in CHO-K1 cells. A, membranes (10 g per lane) from
CHO-K1 cells transiently transfected with the cDNAs corresponding to
the wild-type full-length enzyme (NTPDase2) or the C399S and
N443D mutants of the human ecto-ATPase were subjected to SDS-
PAGE, transferred to nitrocellulose, and the proteins detected with
anti-pentahistidine monoclonal antibodies. The arrow indicates the
fully matured species in NTPDase2, which is absent in both mutants.
B, membranes (20 g per lane) from CHO-K1 cells transiently trans-
fected with the tagged cDNAs of the wild-type full-length enzyme
(NTPDase2) or the C399S and N443D mutants were treated in the
absence () or in the presence () of 500 units of PNGase F for 20 h at
37 °C, according to manufacturer’s instructions. The proteins subse-
quently were separated by SDS-PAGE and analyzed by immunoblotting
with anti-Myc monoclonal antibodies. Prestained molecular size mark-
ers are indicated in kilodaltons.
FIG. 6. Enzymatic activity of the C399S and N443D mutants of
the human ecto-ATPase. CHO-K1 cells (300,000 cells/well) were
seeded into 12-well plates and transfected 24 h later with cDNA for the
wild-type enzyme, the C399S and N443D mutants of the human ecto-
ATPase, or with empty vector. Ecto-ATPase activity was determined
24 h after transfection as a function of time at 37 °C in the presence of
500 M ATP. The inset shows Western blot analysis of lysates from
individual wells containing the equivalent amount of cells tested for
activity. The proteins were detected with anti-pentahistidine mono-
clonal antibodies.
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the ER due to structural misfolding (37). Little ecto-ATPase
activity was observed in membranes of vector-transfected cells
when compared with the activity of cells expressing the ecto-
ATPase (data not shown). Detergent solubilization experi-
ments were carried out to determine whether the forms of the
human ecto-ATPase that did not target the plasma membrane
are nonetheless active. We initially tested whether ecto-
ATPase activity of the full-length wild-type enzyme was re-
tained after solubilization of membranes with Triton X-100,
Nonidet P-40, digitonin, CHAPS, or dodecyl maltoside (Table
I). Only digitonin preserved the enzymatic activity when com-
pared with non-solubilized membranes. Indeed, an increase of
ecto-ATPase activity occurred in the presence of digitonin, sug-
gesting that this detergent releases significant activity en-
closed in membrane vesicles or that is not accessible to the
substrate in intact cell assays. Extraction of equivalent
amounts of protein after solubilization with digitonin (Fig. 9B)
did not uncover significant enzymatic activity of the spliced
forms NTPDase2 and -2 or of the ecto-ATPase mutants (Fig.
9A) or of vector-transfected control cells (data not shown).
These results indicate that the lack/reduction in enzymatic
activity of the shorter splice variants and mutants of the hu-
man ecto-ATPase is not only due to lack of presence at the cell
surface but also due to structural alterations that result in loss
of enzymatic activity.
DISCUSSION
In this study we report the identification and heterologous
expression of three splice variants of the human NTPDase2
gene (2, 2, and 2). Our results show that the region missing
in the shorter splice variants 2 and 2 is essential for correct
folding, trafficking, and enzymatic activity of the human
NTPDase2. Importantly, we demonstrate that Cys399, which is
absent in the shorter isoforms of the human NTPDase2, ac-
counts for the inactive intracellular phenotype shown by 2
and 2. Accordingly, mutation of this residue to a serine in the
FIG. 7. Plasma membrane localization of the splice variants
and mutants of the human ecto-ATPase. Expression at the plasma
membrane of the splice variants and mutants of the human NTPDase2
was analyzed by immunofluorescence and confocal microscopy in
CHO-K1 cells stably expressing the cDNA of each protein. The left
panels are confocal images of cells stained with an anti-Myc antibody
followed by a Texas Red-labeled goat anti-mouse antibody. The middle
panels show staining with fluorescein-labeled phalloidin to delimit the
plasma membrane. The right panels show the overlapping image of
both stains. The green and red channels were independently scanned to
ensure no light emission cross-contamination between the channels.
X-Y confocal planes at the level of the nuclei are shown (objective 40,
NA 1.0 oil, zoom  3, Z step 1 m).
FIG. 8. Subcellular localization of the splice variants and mu-
tants of the human ecto-ATPase. Localization of Myc-His-tagged
enzymes was analyzed by immunofluorescence and confocal microscopy
as described in the legend to Fig. 8. Cells were co-stained with anti-Myc
Ab (red) and TGN38 (green, trans-Golgi network) in the top row or with
anti-Myc Ab (red) and concanavalin A-Alexa 488 (middle column, green,
endoplasmic reticulum). Confocal analysis was performed as described
in the legend to Fig. 7.
TABLE I
Effect of detergent solubilization of the human NTPDase2 on
enzymatic activity.
Total membranes obtained from CHO-K1 cells stably expressing the
human NTPDase2 were solubilized in the presence of each detergent
(1% final concentration) for 1 h on ice. The protein extracts (1 g of
protein per assay) were tested for hydrolytic activity for 10 min at 37 °C,
using 1 mM ATP as the substrate. The assay medium was composed of
120 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1.2 mM MgCl2, 20 mM Tris-Cl, pH
7.4, containing 1% of the corresponding detergent. The results are





Triton X-100 0.20  0.07
Nonidet P-40 0.21  0.03
Digitonin 5.70  0.37
CHAPS 0.17  0.03
Dodecyl maltoside 0.75  0.05
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full-length active isoform (2) recapitulates the defects in proc-
essing and enzymatic activity exhibited by the shorter splice
variants. Our results suggest that Cys399 is involved in an
intra-chain disulfide bond that is essential for acquisition of
tertiary structure and consequently for enzymatic activity of
the human NTPDase2.
We recently described the isolation of a human cDNA encod-
ing a predicted 495 amino acid protein (14). This sequence was
found identical in length and highly homologous to ecto-
ATPases previously reported from rat brain (11), mouse hepa-
toma cells (18), and chicken muscle (13). In the current work
two other human cDNAs were isolated encoding predicted pro-
teins of 472 and 450 amino acids. Sequence analysis of a human
genomic DNA clone indicated that these three sequences cor-
respond to alternative splice variants of the human ecto-
ATPase gene (Fig. 1). The missing regions in NTPDase2 and
-2 are the result of differential splicing of exon eight and
correspond to the extracellular domain of the protein near the
fifth ACR and the COOH terminus. Although the shorter splice
variants of the human ecto-ATPase contain the five ACRs
proposed to be essential for enzymatic activity (15–17), no
ecto-ATPase activity was observed when NTPDase2 and -2
were heterologously expressed in CHO-K1 or NIH-3T3 cells to
levels similar to that of the full-length active enzyme.
The physiological significance of multiple mRNAs for the
human ecto-ATPase, some of which do not produce active en-
zyme when expressed alone, is unknown. Alternative splice
variants also have been described for the rat NTPDase2 (22).
Although it is not known whether alternative messages for the
rat ecto-ATPase are translated into functional enzyme, the
occurrence of alternative splicing in multiple species suggests
it to be a common mechanism for regulation of expression of
these enzymes. Since E-NTPDases form active oligomers (7, 19,
33–35), the shorter splice variants of the human NTPDase2
potentially form hetero-oligomers with the full-length active
isozyme (2) generating biochemical characteristics different
from those of the homo-oligomeric forms. For example, two
splice variants of a human serotonin receptor 5-HT3A, referred
to as truncated (h5-HT3AT) and long (h-5HT3AL), did not as-
semble into functional homomeric ion channels when expressed
individually (38). However, co-expression of either splice vari-
ant with the active h5-HT3A subunit resulted in heteromeric
assembly and in significantly modified 5-HT3A receptor func-
tion. Considering that the message for NTPDase2 is the most
abundant in ECV304 cells (data not shown), its co-assembly
with 2 and/or 2 might serve as a mechanism for modification
of enzymatic activity relative to the oligomeric form composed
exclusively of NTPDase2 subunits. Tissue-specific splicing
patterns yielding hetero-oligomers with varying monomeric
compositions could result in diversification in the termination
of nucleotide signaling.
Analysis of the subcellular localization of the three splice vari-
ants using confocal microscopy indicated that only NTPDase2 is
delivered to the plasma membrane, with NTPDase2 and -2
mainly localized in the ER. Correct folding and oligomerization of
newly synthesized membrane proteins are prerequisites for ex-
port from the ER. In general, misfolded polypeptides or unas-
sembled subunits of oligomeric proteins are retained in this or-
ganelle and ultimately degraded (39, 40). Our data showing lack
of enzymatic activity of NTPDase2 and -2 in both intact and
digitonin-solubilized cells and retention of these variants in the
ER strongly suggest that the shorter splice variants lack a struc-
tural determinant important for correct folding, activity, and
targeting to the plasma membrane of the human ecto-ATPase.
The human ecto-ATPase contains 10 extracellular cysteine
residues that are absolutely conserved among all type 1
(apyrases) and type 2 (ecto-ATPases) E-NTPDases. The con-
served cysteine residues in E-NTPDases are likely involved in
intra- and/or interchain disulfide bonds based both on struc-
ture-function analysis (17, 19, 41) and on their stability to
proteolysis and inhibition of enzymatic activity by dithiothre-
itol (13, 19). Additionally, the cysteine-rich region between
ACR4 and ACR5 (eight conserved cysteines) in NTPDase1 and
-2 recently was proposed to be important for conferring tertiary
structure, and probably catalytic specificity, to these proteins
(20). The region missing in the shorter splice variants
NTPDase2 and -2 contains one of these conserved cysteines,
Cys399, and replacement of this residue by an amino acid un-
able to form disulfide bonds produced a completely inactive
protein (Figs. 6 and 9). Lack of activity was accompanied by
FIG. 9. Enzymatic activity of digitonin-solubilized splice variants and mutants of the human ecto-ATPase. Confluent CHO-K1 cells
were transiently transfected with the cDNAs corresponding to the splice variants or the C399S and N443D mutants of the human ecto-ATPase or
with empty vector. Twenty-four hours after transfection the cells were trypsinized and plated into 24-well plates at 200,000 cells/well. A, intact
cells. Enzymatic activity was determined 48-h after transfection at 37 °C using 1 mM ATP as the substrate. Thereafter, the cells were washed with
PBS, dissolved in reducing Laemmli’s sample buffer, subjected to SDS-PAGE, transferred to nitrocellulose, and probed with anti-Myc antibodies.
B, digitonin-solubilized cells. Another set of transfected cells was solubilized for 60 min at 4 °C in assay buffer containing 1% digitonin. After
solubilization, the extracts were processed as described in the legend to A for both enzymatic activity and immunoblot analysis.
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loss of the more diffuse upper bands at around 75–80 kDa
observed after SDS-PAGE and by a clear ER retention pheno-
type with no enzyme detected at the plasma membrane. These
features of the C399S mutant resemble those found for the
splice variants 2 and 2 and strongly suggest that Cys399 is
the structural determinant absent in 2 and 2 that is essen-
tial for correct folding and trafficking to the plasma membrane.
In general, correct folding of proteins in the ER requires the
early formation of intra-chain disulfide bonds that help to
stabilize domain structure, so that cysteine mutations are fre-
quently damaging, and lack of native disulfide bonds might
lead to protein retention (39, 40, 42). Thus, our results suggest
that Cys399 is implicated in the formation of an intramolecular
disulfide bond essential for protein structure and function of the
human NTPDase2 and give explanation for the lack of activity
found in the shorter splice variants NTPDase2 and -2.
In addition to the absence of Cys399 in the shorter splice
variants of the human ecto-ATPase and the consequent struc-
tural/functional alterations, a different glycosylation pattern is
evident in these forms when compared with the wild-type
NTPDase2 (Figs. 2 and 3). Therefore, the effect of N-glycosy-
lation on enzymatic activity of the human ecto-ATPase also
was investigated, since the lack of activity observed in NTP-
Dase2 and -2 might result from of an impaired glycosylation
as a downstream consequence of an altered disulfide bond.
Glycosylation contributes to correct folding of glycoproteins by
stabilizing protein conformation and preventing the unfolded
or partially folded protein molecules from aggregation (7, 32).
N-Linked oligosaccharides attach to asparagines at Asn-X-Ser/
Thr sequences co-translationally as the polypeptide chains are
translocated across the ER membrane. Core-glycosylated pro-
teins then are trimmed by glucosidases and mannosidases in
the ER and Golgi and are further modified in the Golgi appa-
ratus to full glycosylation (32, 36). Although E-NTPDases are
heavily glycosylated enzymes, the role of N-glycans in enzy-
matic activity has remained unclear. Some studies support
an importance of glycosylation for enzymatic activity of
E-NTPDases (33–35), while others report little or no effect
(17, 23).
The human NTPDase2 possesses six potential consensus
sites for N-glycosylation (14), all of which are present in the
three splice variants. Only two of these, Asn64 and Asn443, are
invariantly conserved among all cloned NTPDases1 and -2.
Since Asn64 (Asn-Asp-Thr) presents a less susceptible site for
glycosylation than Asn443 (Asn-Leu-Thr) due to the presence of
an Asp immediately after Asn64 (36), we studied the potential
role of Asn443. Substitution of Asn443 with an aspartic acid
yielded a protein that was expressed at similar levels to wild-
type enzyme but that retained only 7% of the hydrolytic activ-
ity. We further demonstrated that Asn443 is an actual target for
N-glycosylation in the human ecto-ATPase, since the N443D
mutant lacked one of the major bands of the doublet at 66–70
kDa present in the wild-type enzyme (Figs. 5 and 6). Asn443 is
normally glycosylated in NTPDase2 and -2, since the doublet
was present in the shorter isoforms. The N443D mutant ap-
parently was recognized as misfolded and was retained in the
ER. However, despite impaired trafficking, at least partial
activity (7%) was observed. Although undetectable by means of
the immunofluorescence technique utilized here, we anticipate
that this active protein reached the plasma membrane. Either
the mutant protein partially “escapes” the quality control of the
ER, or perhaps the N443D mutation causes a decrease in the
efficiency of folding and maturation of the core-glycosylated
primary translation product as has been shown for F508
cystic fibrosis transmembrane regulator (43). Taken together,
these results indicate that full glycosylation at position 443 is
essential for correct folding and trafficking of NTPDase2 to the
plasma membrane.
In conclusion, we report here the importance of correct proc-
essing and enzymatic activity of two highly conserved residues
in the human NTPDase2, Cys399 and Asn443, and give expla-
nation for the lack of activity of the shorter splice variants of
the enzyme. The physiological significance of multiple splice
forms of the human ecto-ATPase is under investigation.
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